- Il profilo d’efficacia e sicurezza a lungo termine di ixekizumab nei pazienti con psoriasi è stato valutato nei trial UNCOVER, ma ci sono pochi studi sull’esperienza real-life.
- Il presente studio retrospettivo ha valutato i dati di 779 pazienti affetti da psoriasi moderata-severa trattati con ixekizumab in 11 centri ospedalieri italiani con un follow-up fino a 192 settimane.
Introduction and design
Psoriasis is one of the commonest inflammatory skin diseases determining a very high impact on patients’ quality of life and daily activities and relationships. Several biologic therapies have been approved through the years for the treatment of moderate-to-severe plaque psoriasis, and efficacy and safety profile have been analyzed in clinical trials. Ixekizumab is an immunoglobulin G subclass 4 monoclonal antibody that selectively targets and binds IL-17A with high specificity and affinity. Inhibiting IL-17A activity, ixekizumab reduces and turns down levels of inflammation, resulting in the clinical improvement of the disease.
Results and conclusions
Long-term efficacy and safety profile of ixekizumab have been investigated and reported in the UNCOVER trials, but in literature there are only few studies based on real life experience. We present the efficacy and safety profile of ixekizumab in a cohort of 779 patients affected by moderate-to-severe plaque psoriasis and treated with ixekizumab in 11 Italian dermatology hospitals, with a follow-up of care until 192 weeks.